The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Impact of splicing factor mutations on AML treatment
Curtis Lachowiez, MD, MD Anderson Cancer Center, Houston, TX, discusses a recent paper investigating splicing factor mutations in patients with acute myeloid leukemia (AML). These mutations include SRSF2, SF3B1, U2AF1, and ZRSR2. Dr Lachowiez reports that patients with these mutations trend towards inferior outcomes with intensive chemotherapy. Dr Lachowiez also discusses how advances in technology could benefit this field of research. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
